Mobile Health to Enhance Exercise in Type 2 Diabetes (MOTIVATET2D)
2021年4月26日 更新者:Jonathan Little、University of British Columbia
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes: A Pilot Randomized Trial
Being physically active and exercising is important for the treatment of Type 2 diabetes as it helps control blood sugar and improve physical function.
Lots of people find it hard to be physically active and sticking with exercise is difficult for most people.
In this project we will investigate two strategies to support people with Type 2 diabetes to increase and then maintain a physically active lifestyle, which includes exercising regularly.
Participants in one group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular (virtual) contact with an exercise specialist.
Participants in the second group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
The fitness watch and mobile App will allow the exercise specialist to provide greater support and feedback throughout the programme.
研究概览
研究类型
介入性
注册 (预期的)
120
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Ali McManus, PhD
- 电话号码:250-807-8192
- 邮箱:ali.mcmanus@ubc.ca
研究联系人备份
- 姓名:Matthew S Cocks, PhD
- 电话号码:0151 904 6243
- 邮箱:M.S.Cocks@ljmu.ac.uk
学习地点
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1V1V7
- 招聘中
- University of British Columbia
-
接触:
- Jonathan Low
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Diagnosed with T2D within the previous 5-24 months
- Male or Female
- Aged 40-75
- Treat diabetes with only Metformin or lifestyle modifications (diet and exercise)
- For those prescribed Metformin: have used a stable dose for 3-months or more
Exclusion Criteria:
- Aged under 40 or over 75
- Glycated hemoglobin level (HbA1c) more than 10% (>86mmol/mol)
- Blood pressure higher than 160/110 mmHg
- Treat diabetes with an antidiabetic drug other than Metformin (Sulfonylureas, Thiazolidinedione, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonist, Acarbose, meglitinides)
- Prescription of Insulin
- Unstable angina (frequent chest pain)
- Myocardial infarction (heart attack) within the previous 3 months
- Transient ischemic attack (TIA) within the previous 6 months
- Heart failure ≥class 2
- Arrhythmia
- Inability to increase activity
- Pregnancy or planning to become pregnant
- Less than 6 months post childbirth or stopped breastfeeding less than 1 month ago
- Not owning a smartphone/ or having no data plan or access to WiFi
- currently meeting the recommended exercise guidelines (150 min of moderate intensity exercise per week).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:mHealth Technology
Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
|
A 6 month exercise and physical activity programme supported by an exercise specialist
A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
其他名称:
|
|
有源比较器:Exercise Counselling
Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
|
A 6 month exercise and physical activity programme supported by an exercise specialist
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determine the number of adults with newly diagnosed T2D that are eligible to participate in the trial
大体时间:0-12 months
|
Information will be collected on: - The number of patients approached and reasons for not joining the study |
0-12 months
|
|
The number of these adults with newly diagnosed T2D who would be willing to take part in this trial
大体时间:0-12 months
|
Information will be collected on: - The number of patients who actually enroll |
0-12 months
|
|
The characteristics of these adults with newly diagnosed T2D who are willing to take part in the trial
大体时间:0-12 months
|
Information will be collected on: - Patient gender, age, and how patients are currently treating their T2D |
0-12 months
|
|
The number and percentage of participants retained at 12-months.
大体时间:0-12 months
|
Information will be collected on: - Number and percentage of patients attending at 12-month follow up and reasons for drop-out. |
0-12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adherence to exercise
大体时间:0 months, 0-6 months, 0-12 months
|
Adherence to structured exercise assessed through monthly exercise questionnaire (GLTEQ)
|
0 months, 0-6 months, 0-12 months
|
|
Change in glycaemic control
大体时间:0 months, 0-6 months, 0-12 months
|
Glycated hemoglobin (HbA1c), flash glucose monitoring
|
0 months, 0-6 months, 0-12 months
|
|
Change in body composition
大体时间:0 months, 0-6 months, 0-12 months
|
Height (meters) and weight (kilograms) will be aggregated to arrive at one reported BMI value (kg/m^2)
|
0 months, 0-6 months, 0-12 months
|
|
Change in weight
大体时间:0 months, 0-6 months, 0-12 months
|
Weight (kilograms)
|
0 months, 0-6 months, 0-12 months
|
|
Change in waist circumference
大体时间:0 months, 0-6 months, 0-12 months
|
Waist circumference (centimeters)
|
0 months, 0-6 months, 0-12 months
|
|
Change in blood pressure
大体时间:0 months, 0-6 months, 0-12 months
|
Blood pressure taken with a cuff
|
0 months, 0-6 months, 0-12 months
|
|
Change in blood lipids
大体时间:0 months, 0-6 months, 0-12 months
|
Total cholesterol, high-density lipoprotein, triglycerides, low-density lipoprotein
|
0 months, 0-6 months, 0-12 months
|
|
Diabetes related quality of life
大体时间:0 months, 0-6 months, 0-12 months
|
SF-12 Health Survey and Diabetes Treatment Satisfaction Questionnaire used to assess diabetes related quality of life
|
0 months, 0-6 months, 0-12 months
|
|
Behavioural regulation in exercise
大体时间:0 months, 0-6 months, 0-12 months
|
Assessed using the Behavioural Regulation in Exercise Questionnaire
|
0 months, 0-6 months, 0-12 months
|
|
Patient rapport with counsellor
大体时间:0 months, 0-6 months, 0-12 months
|
Assessed using the Patient Rapport with Counsellor Questionnaire
|
0 months, 0-6 months, 0-12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acceptability and feasibility of the wearable intervention to patients
大体时间:0-6 months, 0-12 months
|
Post-intervention patient questionnaire that will assess the acceptability of the wearable intervention and exposure to other wearable technologies
|
0-6 months, 0-12 months
|
|
Acceptability and feasibility of patients continuing the intervention on their own
大体时间:0-6 months, 0-12 months
|
Follow-up patient questionnaire investigating anticipated barriers and facilitators to continuing the intervention
|
0-6 months, 0-12 months
|
|
Pilot methods for collecting outcome measures
大体时间:Approx. 1 month after baseline
|
Early acceptability questionnaire investigating the acceptability of the measurement instruments and their ease of use.
|
Approx. 1 month after baseline
|
|
Ensure that our plans for recruitment, randomisation, treatment, and follow-up are acceptable to patients
大体时间:0-12 months
|
Post intervention patient questionnaire investigating the acceptability of the recruitment and randomisation process and the measurement instruments
|
0-12 months
|
|
Determine availability and completeness of economic data
大体时间:0 months, 0-6 months, 0-12 months
|
5-level EQ-5D Questionnaire
|
0 months, 0-6 months, 0-12 months
|
|
Determine healthcare usage
大体时间:0 months, 0-6 months, 0-12 months
|
Questionnaire assessing healthcare usage in the last 12 weeks
|
0 months, 0-6 months, 0-12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2021年2月1日
初级完成 (预期的)
2022年12月1日
研究完成 (预期的)
2023年5月1日
研究注册日期
首次提交
2020年11月19日
首先提交符合 QC 标准的
2020年11月26日
首次发布 (实际的)
2020年12月4日
研究记录更新
最后更新发布 (实际的)
2021年4月28日
上次提交的符合 QC 标准的更新
2021年4月26日
最后验证
2021年4月1日
更多信息
与本研究相关的术语
其他研究编号
- H20-01936
- 20/SS/0101 (其他标识符:South East Scotland Research Ethics Committee)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
Pseudonymised data from this study will be made available for sharing with other investigators, after publication of the study's key papers.
Data will be shared through the LJMU Data Repository (http://opendata.ljmu.ac.uk/).
This is a secure institutional data repository, which is searchable on the www, it is managed by Library Services.
A DOI will be generated for datasets as they are deposited to the repository.
Data will be stored in this repository for a minimum of 10 years or for 10 years from the last date of access.
IPD 共享时间框架
Data will be stored in this repository for a minimum of 10 years or for 10 years from the last date of access.
IPD 共享访问标准
Data will be shared through the LJMU Data Repository (http://opendata.ljmu.ac.uk/).
This is a secure institutional data repository, which is searchable on the www, it is managed by Library Services.
A DOI will be generated for datasets as they are deposited to the repository.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.